Methods and compositions for inhibiting angiogenesis

Details Methods and compositions for inhibiting angiogenesis Methods and compositions for inhibiting angiogenesis

2007-01-05

2009-12-01

Fetterolf, Brandon J (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S130100, C424S138100, C424S141100, C424S158100

Reexamination Certificate

active

07625868

ABSTRACT:
Methods for inhibiting angiogenesis in endothelial cells and selectively inducing apoptosis in endothelial cells via compounds which binds annexin II are provided. These compounds and methods for using these compounds are useful in the treatment of diseases or disorders characterized by unwanted angiogenesis. Also provided are pharmaceutical compositions containing a compound which binds annexin II and a pharmaceutically acceptable vehicle and methods for identifying such compounds.

REFERENCES:
patent: 5051364 (1991-09-01), Isacke et al.
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: WO 98/54217 (1998-03-01), None
patent: WO 99/48916 (1999-09-01), None
patent: WO 00/11033 (2000-02-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Jain (Scientific American Jul. 1994).
MSNBC News Services, “Mixed results on new cancer drug”, Nov. 9, 2000.
Gura (Science, v278, 1997, pp. 1041-1042).
Sim et al. (Cancer Research, vol. 57, 1997).
Aarli et al., “Inhibition of phytohaemagglutinin-induced lymphoproliferation by soluble annexin II in sera from patients with renal cell carcinoma”, APMIS 1997 105:699-704.
Chung et al., “Cell Surface Annexin II Is a High Affinity Receptor for the Alternatively Spliced Segment of Tenascin-C”, J. Cell Biol. 1994 126:539-548.
Sim et al., “A Recombinant Human Angiostatin Protein Inhibits Experimental Primary and Metastatic Cancer1”, Cancer Research 1997 57:1329-1334.
Moser et al., “Angiostatin binds ATP synthase on the surface of human endothelial cells”, Proc. Natl. Acad. Sci. USA 1999 96:2811-2816.
Ulvestad et al., “Identification of a soluble Fcγ-binding molecule (annexin II) in human serum using a competitive ELISA”, APMIS 1994 102:667-673.
Archarya et al., “Annexin II:Potential Role in Plasmin-Mediated Invasion of Malignant Glioma Cells”, Blood 1998 92(10) Suppl. 1 Part 1-2:42a XP009024406.
Balch et al., “Annexins II and V Inhibit Cell Migration”, Experimental Cell Research 1997 237:259-263 XP-002268193.
Hajjar et al., “Annexin II and Regulation of Cell Surface Fibrinolysis”, Annals of the New York Academy of Sciences 2000 265-271 XP009024460.
Hajjar et al., “New Concepts in Fibrinolysis and Angiogenesis”, Current Atherosclerosis Reports 2000 2:417-421 XP009024206.
O'Reilly et al., “Angiostatin:A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma”, Cell 1994 79:315-328 XP002015254.
Siever et al., “Molecules in Focus—Extracellular Annexin II”, Int. J. Biochem. Cell Biol. 1997 29(11) :1219-1223 XP-002268192.

Affiliated with

Also associated with

Rating

Methods and compositions for inhibiting angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for inhibiting angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for inhibiting angiogenesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4145331